Pharmacenter Hungary has developed two oncology drugs in a HUF 535 million project, supported by a HUF 298m grant from the National Research, Development and Innovation Fund, the company said in a statement.
The project started in October 2021 and was completed in September 2025.
One of the resulting products is used in the therapy of chronic myelogenous leukemia, head and neck spindle cell tumors. It is included in the EU's critical medicines list and is now commercially available, allowing Hungarian patients access to the drug from multiple sources.
The other product developed in the project has bisphosphonate as its active ingredient, used in the treatment of bone metastases. The application for licensing the product has been submitted in Hungary, and long-term stability studies are in progress.
Pharmacenter Hungary aims to ensure affordable, safe and modern oncology therapies. Their strategic goal is also to utilise the results of the developments on export markets.
The company had revenue of HUF 4.47 billion last year, public records show.
Top 5 Articles
Duna House Profit Climbs Nearly 70% in Q3 November 24, 2025 
What Awaits the Hungarian Economy in 2026 and 2027? April 24, 2026 
'Recharge' Campaign Launched to Boost Domestic Tourism January 21, 2026 
Richter Earnings Slip as Financial Loss Weighs November 6, 2025 
Hungary’s Growth Stalls as Inflation Returns to Target Range February 6, 2026
